Proper blood pressure assessment
National Committee on Detection, Evaluation and Treatment
of High Blood Pressure: The Seventh Report of the Joint National
Committee on Detection, Evaluation and Treatment of High Blood
Pressure (JNC 7). National Institutes of Health, National Heart,
Lung and Blood Institute, 2003 http://www.nhlbi.nih.gov/
guidelines/hypertension/
ACE inhibitor as 1t line therapy in Diabetes Mellitus
National Committee on Detection, Evaluation and Treatment
of High Blood Pressure: The Seventh Report of the Joint National
Committee on Detection, Evaluation and Treatment of High Blood
Pressure (JNC 7). National Institutes of Health, National Heart,
Lung and Blood Institute, 2003 http://www.nhlbi.nih.gov/
guidelines/hypertension/
Kasiske BL, Kalil RS, Ma JZ, et al.: Effect of antihypertensive
therapy on the kidney in patients with diabetes: a meta-regression
analysis. Ann Intern Med 118:129–38, 1993
UK Prospective Diabetes Study Group: Efficacy of atenolol and
captopril in reducing the risk of macrovascular complications in
type 2 diabetes (UKPDS 39) BMJ 317:713–20, 1998
The Heart Outcomes Prevention Evaluation Study. Effects of
an ACE inhibitor, ramipril, on cardiovascular events in high risk
patients. N Engl J Med 342:145–53, 2000
Pahor M, Psaty BM, Alderman MH, et al. Therapeutic benefits of
ACE inhibitors and other antihypertensive drugs in patients with
type 2 diabetes. Diabetes Care 23:888-
9
2, 2000
Wing LMH, Reid CM, Ryan P, et al. A comparison of outcomes
with angiotensin-converting-enzyme inhibitors and diuretics for
hypertension in the elderly (ANBP2). N
E
ngl J Med 348:583-92,
2003
Diuretic as second line
National Committee on Detection, Evaluation and Treatment
of High Blood Pressure: The Seventh Report of the Joint National
Committee on Detection, Evaluation and Treatment of High Blood
Pressure (JNC 7). National Institutes of Health, National Heart,
Lung and Blood Institute, 2003
http://www.nhlbi.nih.gov/guidelines/hypertension/
Antihypertensive & Lipid Lowering Treatment to Prevent Heart
Attack (ALLHAT) JAMA 288:2981-97, 2002
Beta-Blocker as second line
National Committee on Detection, Evaluation and Treatment
of High Blood Pressure: The Seventh Report of the Joint National
Committee on Detection, Evaluation and Treatment of High Blood
Pressure (JNC
7
). National Institutes of Health, National Heart,
Lung and Blood Institute, 2003
http://www.nhlbi.nih.gov/guidelines/hypertension/
UK Prospective Diabetes Study Group: Efficacy of atenolol and
captopril in reducing the risk of macrovascular complications in
type 2 diabetes
(UKPDS 39) BMJ 317:713–20, 1998
Hansson L, Lindholm LH, Niskanen L, et al. Effect of
angiotensin converting-enzyme inhibition compared with
conventional therapy on cardiovascular morbidity and mortality
in hypertension: the Captopril Prevention Project (CAPPP)
randomised trial. Lancet 353: 611–16, 1999
Verapamil or Diltiazem
Hansson L, Hedner T, Lund-Johansen P, et al. Randomized
trial of effects of calcium antagonists compared with diuretics
and beta-blockers on cardiovascular morbidity and mortality in
hypertension. NORDIL. Lancet 356:359–65, 2000
Bakris GL, Copley JB, Vicknair N, et al. Calcium channel
blockers versus other antihypertensive therapies on progression of
NIDDM associated nephropathy. Kidney Int 50:1641–50, 1996
Dihydropyridine calcium
channel blockers
Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effect of
calcium channel blockage in older patients with diabetes and
systolic hypertension. N Engl J Med 340:677–84, 1999
Dahlof B, Sever P, Poulter N, et al. Prevention of cardiovascular
events with an antihypertensive regimen of amlodipine
adding perindopril as required versus atenolol adding
bendroflumethiazide as required, in the Anglo-Scandinavian
Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-
BPLA): a multicentre randomised controlled trial. Lancet 366:
895-906, 2005
Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine
as compared with enalapril on cardiovascular outcomes in
patients with non-insulin-dependent diabetes and hypertension.
N Engl J Med 338:645–52, 1998
Alpha-Blockers
Major cardiovascular events in hypertensive patients randomized
to doxazosin vs chlorthalidone. (ALLHAT Data) JAMA
283:1967–75, 2000
Blood Pressure Goal <130/80
American Diabetes Association: Clinical Practice
Recommendations 2004. Diabetes Care 27 (suppl 1):S15-S35;
S65-S67, 2004
Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive
blood-pressure lowering and low-dose aspirin in patients with
hypertension: principal results of the Hypertension Optimal
Treatment (HOT) randomised trial. Lancet 351:1755–62, 1998
Tight blood pressure control and risk of macrovascular and
microvascular complications in type 2 diabetes: UKPDS 38 BMJ
317:703–13, 1998
Urine Protein Excretion >1 gram/ 24 hour BP goal
<125/75
Peterson JC, Adler S, Burkart JM, et al. Blood pressure
control, proteinuria, and the progression of renal disease. The
Modification of Diet in Renal Disease Study. Ann Intern Med
123:754– 62, 1995
Angiotensin Receptor Blockers
Renoprotective effect of the angiotensin-receptor antagonist
irbesartan in patients with nephropathy due to type 2 diabetes. N
Engl J Med 345: 851–60, 2001
Effects of losartan on renal and cardiovascular outcomes in
patients with type 2 diabetes and nephropathy. N Engl J Med
345:861–69, 2001
Effects of irbesartan on the development of diabetic nephropathy
in patients with type 2 diabetes. N Engl J Med 345:870–78, 2001
African Americans
Wright JT, Dunn JK, Cutler JA, et al. Outcomes in hypertensive
black and nonblack patients treated with chlorthalidone,
amlodipine, and lisinopril. JAMA 293:1595 -1607, 2 0 05
Wright JT, Bakris G, Greene T, et al. Effect of blood pressure
lowering and antihypertensive drug class on progression of
hypertensive kidney disease: results from the AASK Trial. JAMA
288:2421-31, 2002
Hypertension AlgoritHm for DiAbetes in ADults
2 of 2 – Hypertension Algorithm for Diabetes in Adults – Revised 1/26/12 See disclaimer at www.tdctoolkit.org/algorithms_and_guidelines.asp
Diabetes treatment algorithms